PHIL and Sprout Pharmaceuticals Enhance Access to Addyi, Revolutionizing Women's Health
In a groundbreaking move to improve women's health, PHIL, a tech-driven patient access platform, has partnered with Sprout Pharmaceuticals to enhance the accessibility of their medication, Addyi (flibanserin). This innovative program is designed to ensure that patients can access the treatment they need conveniently and affordably. Through this expansion, costs for patients can be as low as $40 annually with commercial insurance or $149 a month for those paying out-of-pocket.
The direct-to-patient program for Addyi addresses the long-standing issues of accessibility in women's sexual health. Now, both telehealth services and in-person visits can facilitate a smoother prescription process, allowing women to receive their medication promptly. Importantly, the program offers free home delivery across the United States, making it easier for women to maintain their therapy.
Cindy Eckert, CEO of Sprout Pharmaceuticals, emphasized the significance of affordable access, stating, "The best patient experience begins with affordable access." With this program, 80% of Addyi patients now pay less than $100 monthly, and more than half achieve costs of just $40 per year with insurance coverage. This collaborative effort aims to dismantle the barriers that have historically obstructed women's access to vital healthcare solutions.
Addyi stands out as the only FDA-approved medication targeting hypoactive sexual desire disorder (HSDD) in women, making it a pivotal therapy for those experiencing distress related to low sexual desire. The recent FDA approval broadens its indication to women under 65, further solidifying the role of Addyi in women's health.
A significant component of this program is the PHILRx service, which provides a user-friendly interface for healthcare providers to send prescriptions directly from their electronic medical record systems. This seamless integration ensures that patients can commence therapy without unnecessary delays, ultimately helping them adhere to their treatment plans through proactive refill support.
Deepak Thomas, Founder and CEO of PHIL, expressed the importance of a modern medication access experience, stating, "Patients deserve a medication access experience that's as modern as the science." The strategic partnership with Sprout Pharmaceuticals aims to address the consistent barriers women face in obtaining essential therapies for HSDD.
As PHIL and Sprout Pharmaceuticals work together to enhance access to Addyi, they are not just transforming how women receive treatment; they are fundamentally changing the narrative around women’s health. Through innovative technology, compassionate patient support, and a commitment to removing barriers, their initiative promises to offer women the dignity and care they deserve. For more information on how PHIL is revolutionizing patient access and to learn more about the Addyi program, visit phil.us/addyi.
Key Features of the Program
The direct-to-patient program for Addyi addresses the long-standing issues of accessibility in women's sexual health. Now, both telehealth services and in-person visits can facilitate a smoother prescription process, allowing women to receive their medication promptly. Importantly, the program offers free home delivery across the United States, making it easier for women to maintain their therapy.
Cindy Eckert, CEO of Sprout Pharmaceuticals, emphasized the significance of affordable access, stating, "The best patient experience begins with affordable access." With this program, 80% of Addyi patients now pay less than $100 monthly, and more than half achieve costs of just $40 per year with insurance coverage. This collaborative effort aims to dismantle the barriers that have historically obstructed women's access to vital healthcare solutions.
Transforming Women's Sexual Health
Addyi stands out as the only FDA-approved medication targeting hypoactive sexual desire disorder (HSDD) in women, making it a pivotal therapy for those experiencing distress related to low sexual desire. The recent FDA approval broadens its indication to women under 65, further solidifying the role of Addyi in women's health.
A significant component of this program is the PHILRx service, which provides a user-friendly interface for healthcare providers to send prescriptions directly from their electronic medical record systems. This seamless integration ensures that patients can commence therapy without unnecessary delays, ultimately helping them adhere to their treatment plans through proactive refill support.
Deepak Thomas, Founder and CEO of PHIL, expressed the importance of a modern medication access experience, stating, "Patients deserve a medication access experience that's as modern as the science." The strategic partnership with Sprout Pharmaceuticals aims to address the consistent barriers women face in obtaining essential therapies for HSDD.
Conclusion
As PHIL and Sprout Pharmaceuticals work together to enhance access to Addyi, they are not just transforming how women receive treatment; they are fundamentally changing the narrative around women’s health. Through innovative technology, compassionate patient support, and a commitment to removing barriers, their initiative promises to offer women the dignity and care they deserve. For more information on how PHIL is revolutionizing patient access and to learn more about the Addyi program, visit phil.us/addyi.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.